Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor...

Related Keywords

Canada ,Brazil ,Davidr Gandara ,Andrea Ferris ,Georged Yancopoulos ,Regeneron Velocimmune ,Taylor Ramsey ,Vesna Tosic ,Regeneron Pharmaceuticals ,Prnewswire Regeneron Pharmaceuticals Inc ,Regeneron Pharmaceuticals Inc ,University Of California Davis Comprehensive Cancer Center ,Twitter ,Regeneron Genetics Center ,Drug Administration ,Regeneron Velocimmune Technology ,Nasdaq ,Senior Advisor Of The Thoracic Oncology Program ,Exchange Commission ,Professor Emeritus ,Senior Advisor ,Thoracic Oncology Program ,California Davis Comprehensive Cancer ,Chief Scientific Officer ,Non Small Cell ,Lung Cancer ,Nonproprietary Naming ,Biological Products Guidance ,Prescribing Information ,Chief Scientific Officer George ,Forward Looking Statements ,Product Candidates ,